Mindray's 2020 financial report: revenue of 21.026 billion yuan, a 42% increase in net profit, and a 27% increase in R&D investment

On April 28, Mindray Medical (300760.
SZ) announced its 2020 annual report
.

The report shows that in 2020, Mindray Medical’s operating income is approximately 21.
026 billion yuan, a year-on-year increase of 27%; the net profit attributable to shareholders of listed companies in 2020 is approximately 6.
658 billion yuan, a year-on-year increase of 42.
24%
.

Previously, Mindray Medical proposed to increase the proportion of overseas business to 70%.
The latest financial report shows that Mindray Medical’s overseas will be approximately 9.
916 billion in 2020, accounting for 47.
16%
.

Regarding the main performance drivers in 2020, Mindray said that in 2020, with the global outbreak of the new crown epidemic, monitors, ventilators, infusion pumps and portable color Doppler ultrasound and mobile DR for medical imaging services for life information and support businesses There has been a substantial increase in the demand for life information and support services
.

Starting from the second quarter of 2020, the company began to export COVID-19 IgG/IgM antibody detection reagents to overseas markets, which made up for part of the impact of the epidemic on the in vitro diagnostic business.
At the same time, thanks to the gradual recovery of domestic conventional reagent consumption, the in vitro diagnostic business is reporting Accelerated recovery was achieved during the period
.

After the test of this round of the epidemic, the company's brand influence and recognition in the domestic and international markets have been greatly improved, and breakthroughs have been achieved in many high-end market customer groups, bringing more opportunities for the company's future growth
.

At the same time, the company continued to strengthen internal management to improve operating efficiency, and was affected by the reduction in marketing and travel during the epidemic period, and its operating performance showed a healthy and good growth trend
.

As of the close on the 28th, Mindray Medical has offered 456 yuan per share, with a market value of 554.
3 billion yuan
.

Mindray Medical was listed on the New York Stock Exchange in 2006 and returned to China after being privatized in 2016.
At the time of delisting, its market value was 23 billion yuan (3.
3 billion US dollars)
.

       It is worth noting that Mindray released the first quarter report of 2021 in the same period today
.